U.S., Feb. 13 -- ClinicalTrials.gov registry received information related to the study (NCT06821529) titled 'Stereotactic Intracerebral Injection of IPSC-DAPs in Patients with Parkinson's Disease' on Feb. 04.
Brief Summary: Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments primarily manage symptoms but do not halt or reverse neuronal loss. Cellular replacement therapy has emerged as a potential strategy to restore dopaminergic function and address the underlying neuronal deficits. This study aims to evaluate the safety, feasibility, and efficacy of transplanting dopaminergic neurons into the b...